Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FluiSédal is an oral syrup formulation developed by Laboratoire des Réalisations Thérapeutiques ELERTE for the management of respiratory symptoms associated with ear, nose, and throat (ENT) disorders. It is a combination product containing mequitazine, guaifenesin, and sodium benzoate. Mequitazine is a first-generation H1-antihistamine that provides symptomatic relief for coughs with an allergic component by acting as a selective H1-receptor antagonist. Guaifenesin and sodium benzoate function as expectorants; guaifenesin reduces the viscosity of bronchial secretions to facilitate clearance, while sodium benzoate acts as a mild stimulant expectorant. This specific version of FluiSédal is distinguished by the absence of promethazine, utilizing mequitazine as the antihistamine component instead. It is approved for the symptomatic treatment of bothersome non-productive and productive coughs, particularly those exacerbated by allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mequitazine + guaifenesin + sodium benzoate.